|Saniona AB -- Sweden Stock|| |
SEK 29.65 0.75 2.60%
Co-Founder and Chief Scientific Officer
Dr. Palle Christophersen, Ph.D. has served as Chief Scientific Officer at Saniona AB since 2014. He is also CoFounder of the Company. He joined NeuroSearch in 1991 as Research Scientist in electrophysiology and served as project manager from 1994, where he developed the NeuroPatch system and discovered Endovion for sickle cell anaemia and cancer. From 20042011, he served as Director of In Vitro Pharmacology, and was in 2006 appointed Vice President and member of the NeuroSearch VP management group. He has authored more than 60 peerreviewed articles and is inventor of more than 60 patents. He is Chief Scientific Officer at Saniona AS. He holds a Doctorate in Philosophy in Physiology from the University of Copenhagen.
Age: 58 Founder Since 2014 Ph.D
45 70 70 52 25 http://www.saniona.com
The company has return on total asset (ROA)
of (46.83) %
which means that it has lost $46.83 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (78.03) %
meaning that it generated substantial loss on money invested by shareholders.
Saniona AB , a research and development company, engages in the discovery and development of drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain in Denmark. Saniona AB was founded in 2011 and is headquartered in Ballerup, Denmark. Saniona AB operates under Pharmaceuticals And Biosciences classification in Sweden and traded on Stockholm Stock Exchange exchange. It employs 22 people.Saniona AB (SANION) is traded on Stockholm Stock Exchange in Sweden. It is located in Baltorpvej 154 and employs 22 people.